Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Single-cell multi-omic analysis of 300,000 cells from 29 patients representing peripheral immune cells and colon mucosal immune, epithelial and mesenchymal cells reveals crosstalk between circulating and tissue-resident immune cells with epithelial cells in checkpoint inhibitor colitis and identifies potential therapeutic targets.
A randomized controlled trial showed that following a personalized dietary program led to significant improvements in cardiometabolic and gut health as well as reductions in body weight compared to following standard dietary advice according to US Department of Agriculture guidelines.
The study on APOE4 homozygosity indicates a genetic variant of Alzheimer’s disease with early symptom onset and distinct biomarker progression, highlighting the need for specialized treatment approaches.
In a tumor-agnostic phase 2 basket trial, the oral FGFR1–FGFR3 inhibitor pemigatinib elicits responses in tumor types beyond cholangiocarcinoma and bladder cancer and in tumor types with rarer FGFR alterations, with insights provided into resistance mechanisms.
Post hoc analysis of the DAPA-HF and DELIVER trials reports on the approach of win statistics to evaluate the effect of dapagliflozin on a hierarchical composite kidney outcome in patients with heart failure.
In a prospective study, a team-based approach combining continuous glucose monitoring with a technology-assisted remote patient monitoring program improved glycemia in a diverse cohort of children, adolescents and young adults with newly diagnosed type 1 diabetes.
Using exome sequencing data from one of the largest cohorts of children with cerebral palsy, the genetic diagnostic rates of single-nucleotide and copy number variants were assessed and a sizeable fraction found to be clinically actionable.
The dynamics and durability of immune responses associated with protection against symptomatic infection in children offer insights to guide vaccination policies in pediatric populations.
In an open-label phase 2 trial, patients with non-small-cell lung cancer received neoadjuvant anti-PD-1 with or without anti-LAG-3, showing that curative intent surgery after combined blockade of PD-1 and LAG-3 is feasible, and leads to preliminary clinical responses.
A vision–language foundation model, trained on a dataset of more than 1 million echocardiogram video–text pairs, is able to assess various cardiac structural and functional parameters despite not having been directly trained on any specific image interpretation task.
In a randomized clinical trial, alerts based on the detection of abnormalities in electrocardiograms using a deep learning algorithm reduced all-cause mortality at 90 days in patients admitted to hospital emergency or internal medicine departments.
In a case series of six patients with multidrug-resistant rheumatoid arthritis, the CD19xCD3-targeting bispecific T cell engager blinatumomab reduced disease activity and led to reductions in autoantibodies.
Tailored to detect and prevent potential medication direction errors in a digital pharmacy data processing pipeline, a large language model is shown to increase efficiency and decrease burden for technicians and pharmacists in a prospective application.
In a phase 2 trial, nivolumab achieved a response rate of 58% in patients with mismatch-repair-deficient gynecological cancers, meeting the primary endpoint, and genomic and immunologic features correlated with response.
An antibody screen of two distinct multiple sclerosis cohorts reveals an autoantibody signature that is detectable years before symptom onset and linked to a common microbial motif.
In a series of clinically relevant tasks in computational pathology, AI-driven models display marked performance disparities across demographic groups, which can only partially be mitigated by self-supervision on large training datasets and existing debiasing techniques.
Implementation of organized low-dose computed tomography screening in over 4,000 individuals with high risk for lung cancer as part of the Ontario Lung Cancer Screening Pilot reported high cancer detection rates, early detection of cancer and low serious harms.
The QR4 algorithm for prediction of 10-year cardiovascular disease risk, developed, tested and externally validated in datasets comprising 16.8 million people from the United Kingdom, improves upon the QRISK3 algorithm that is in current use by incorporating new risk factors.
A self-amplifying mRNA vaccine shows promise in this new modality by eliciting neutralizing antibodies against the SARS-CoV-2 Omicron (BA.1) variant in a phase 2/3 trial.